Loading...

Canbiola

OTCPK:CANB
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CANB
OTCPK
$23M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Canbiola Inc. develops and sells cannabidiol (CBD) based products for pain, insomnia, epilepsy, anxiety, inflammation, and nausea in the United States. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Canbiola has significant price volatility in the past 3 months.
CANB Share Price and Events
7 Day Returns
1.3%
OTCPK:CANB
-3.8%
US Pharmaceuticals
0.6%
US Market
1 Year Returns
178.6%
OTCPK:CANB
3.4%
US Pharmaceuticals
4.1%
US Market
CANB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Canbiola (CANB) 1.3% -18.2% -18.8% 178.6% -22% 30%
US Pharmaceuticals -3.8% -1% 1% 3.4% 1.5% 12.6%
US Market 0.6% 3.8% 2.8% 4.1% 37.3% 42.5%
1 Year Return vs Industry and Market
  • CANB outperformed the Pharmaceuticals industry which returned 3.4% over the past year.
  • CANB outperformed the Market in United States of America which returned 4.1% over the past year.
Price Volatility
CANB
Industry
5yr Volatility vs Market

Value

 Is Canbiola undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Canbiola is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Canbiola has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Canbiola. This is due to cash flow or dividend data being unavailable. The share price is $0.039.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Canbiola's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Canbiola's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CANB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.02
OTCPK:CANB Share Price ** OTCPK (2019-07-17) in USD $0.04
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.04x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Canbiola.

OTCPK:CANB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:CANB Share Price ÷ EPS (both in USD)

= 0.04 ÷ -0.02

-2.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Canbiola is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Canbiola is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Canbiola's expected growth come at a high price?
Raw Data
OTCPK:CANB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.75x
United States of America Market PEG Ratio Median Figure of 2,122 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Canbiola, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Canbiola's assets?
Raw Data
OTCPK:CANB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.00
OTCPK:CANB Share Price * OTCPK (2019-07-17) in USD $0.04
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 185 Publicly-Listed Pharmaceuticals Companies 3.18x
United States of America Market PB Ratio Median Figure of 5,241 Publicly-Listed Companies 1.81x
OTCPK:CANB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:CANB Share Price ÷ Book Value per Share (both in USD)

= 0.04 ÷ 0.00

-60.84x

* Primary Listing of Canbiola.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Canbiola has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.

Next steps:

  1. Examine Canbiola's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Show me more potentially undervalued companies in the Pharmaceuticals industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Canbiola's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Canbiola has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Canbiola expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Canbiola has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.4%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Canbiola expected to grow at an attractive rate?
  • Unable to compare Canbiola's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Canbiola's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Canbiola's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:CANB Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.4%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CANB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CANB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -1 -6
2018-12-31 1 -1 -4
2018-09-30 0 -1 -6
2018-06-30 0 0 -2
2018-03-31 0 0 -2
2017-12-31 0 0 -2
2017-09-30 0 0 -1
2017-06-30 0 0 -1
2017-03-31 0 0 0
2016-12-31 0 0 -1
2016-09-30 0 0 -1
2016-06-30 0 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Canbiola is high growth as no earnings estimate data is available.
  • Unable to determine if Canbiola is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CANB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Canbiola Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CANB Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.02
2018-12-31 -0.01
2018-09-30 -0.03
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00
2016-06-30 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Canbiola will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Canbiola's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Canbiola's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Canbiola's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Canbiola's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Canbiola has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Canbiola performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Canbiola's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Canbiola does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Canbiola's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Canbiola's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Canbiola's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Canbiola Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CANB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1.12 -5.69 4.02
2018-12-31 0.67 -4.11 3.43
2018-09-30 0.44 -6.40 2.03
2018-06-30 0.30 -2.22 1.52
2018-03-31 0.17 -1.76 1.17
2017-12-31 0.12 -2.14 0.64
2017-09-30 0.09 -0.79 0.47
2017-06-30 0.09 -0.92 0.42
2017-03-31 0.09 -0.50 0.34
2016-12-31 0.10 -0.67 0.42
2016-09-30 0.10 -0.50 0.49
2016-06-30 0.09 -0.80 0.81
2016-03-31 0.09 -1.29 1.23
2015-12-31 0.11 -3.59 1.52
2015-09-30 0.09 -3.43 1.39
2014-12-31 0.01 -0.03 0.00
2013-12-31 0.02 -0.48 0.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Canbiola has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Canbiola has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Canbiola improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Canbiola's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Canbiola has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Canbiola's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Canbiola's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Canbiola is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Canbiola's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Canbiola's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 78.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Canbiola Company Filings, last reported 3 months ago.

OTCPK:CANB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 4.20 0.02 0.72
2018-12-31 3.49 0.02 0.81
2018-09-30 0.62 0.14 0.38
2018-06-30 0.03 0.26 0.07
2018-03-31 0.58 0.24 0.05
2017-12-31 -1.73 0.19 0.00
2017-09-30 -0.65 0.16 0.00
2017-06-30 -0.80 0.15 0.00
2017-03-31 -0.41 0.13 0.03
2016-12-31 -0.51 0.06 0.03
2016-09-30 -0.19 0.09 0.00
2016-06-30 -0.11 0.07 0.00
2016-03-31 -0.02 0.06 0.00
2015-12-31 0.10 0.01 0.02
2015-09-30 0.29 0.01 0.16
2014-12-31 0.02 0.00 0.10
2013-12-31 -0.14 0.05 0.01
  • Canbiola's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).
  • Canbiola had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Canbiola has less than a year of cash runway based on current free cash flow.
  • Canbiola has less than a year of cash runway if free cash flow continues to grow at historical rates of 68.3% each year.
X
Financial health checks
We assess Canbiola's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Canbiola has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Canbiola's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Canbiola dividends.
If you bought $2,000 of Canbiola shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Canbiola's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Canbiola's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CANB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Canbiola has not reported any payouts.
  • Unable to verify if Canbiola's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Canbiola's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Canbiola has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Canbiola's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Canbiola afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Canbiola has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Canbiola's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marco Alfonsi
COMPENSATION $104,500
AGE 58
TENURE AS CEO 4.5 years
CEO Bio

Mr. Marco Alfonsi serves as the Chief Executive Officer and Chairman of the Board of Director at Canbiola, Inc since October 21, 2018. He served as a Interim Secretary, Chief Financial Officer at Canbiola, Inc until October 21, 2018. He served as Interim Chairman and Chief Financial Officer of WrapMail, Inc. since December 23, 2016. Mr. Alfonsi co-founded Prosperity Systems Inc. in 2008 and serves as its Chairman and Chief Executive Officer. He is a financial service professional. Prior to his involvement in the financial services industry, Mr. Alfonsi has owned, operated, financed and sold several businesses. Mr. Alfonsi successfully started and managed two companies (ExecuteDirect.com and Bakers Express of New York, Inc.) and held senior management positions with a number of financial institutions: Global American Investments, Clark Street Capital, Basic Investors. Mr. Alfonsi served as the Chief Operating Officer of Tire International Environmental Solutions Inc. from August 16, 2010 to June 27, 2011. From 1996 to 2008, he held several positions and licenses in the financial services industry where he was involved in the corporate finance of several publicly traded and private companies. He has been a Director at Canbiola, Inc. since January 2015. Mr. Alfonsi served as a Director of Tire International Environmental Solutions Inc. from August 16, 2010 to June 27, 2011. He is an entrepreneur.

CEO Compensation
  • Marco's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Marco's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Canbiola management team in years:

1.8
Average Tenure
57.5
Average Age
  • The average tenure for the Canbiola management team is less than 2 years, this suggests a new team.
Management Team

Marco Alfonsi

TITLE
CEO & Chairman of the Board of Directors
COMPENSATION
$105K
AGE
58
TENURE
4.5 yrs

Stan Teeple

TITLE
CFO, Secretary & Director
COMPENSATION
$308K
AGE
67
TENURE
0.8 yrs

David Posel

TITLE
Chief Operating Officer of Pure Leaf Oil
COMPENSATION
$119K
AGE
40
TENURE
0.5 yrs

Andrew Holtmeyer

TITLE
Executive Vice President of Business Development
COMPENSATION
$1M
AGE
57
TENURE
1.4 yrs

Greg Partin

TITLE
Chief Information Officer
TENURE
4.3 yrs

Smita Ohri

TITLE
Member of Medical Advisory Board
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the Canbiola board of directors in years:

1.4
Average Tenure
64
Average Age
  • The average tenure for the Canbiola board of directors is less than 3 years, this suggests a new board.
Board of Directors

Marco Alfonsi

TITLE
CEO & Chairman of the Board of Directors
COMPENSATION
$105K
AGE
58
TENURE
0.8 yrs

Stan Teeple

TITLE
CFO, Secretary & Director
COMPENSATION
$308K
AGE
67
TENURE
0.8 yrs

Smita Ohri

TITLE
Member of Medical Advisory Board
TENURE
2.2 yrs

Patrick Fratellone

TITLE
Member of Medical Advisory Board
TENURE
1.8 yrs

Robert Kornfeld

TITLE
Member of Medical Advisory Board
TENURE
1.7 yrs

Maciej Ferenc

TITLE
Member of Medical Advisory Board
TENURE
1.4 yrs

Channing Coe

TITLE
Member of Medical Advisory Board
TENURE
1.4 yrs

John Salerno

TITLE
Member of Medical Advisory Board
TENURE
1.8 yrs

David Weissberg

TITLE
Member of Medical Advisory Board
AGE
64
TENURE
0.8 yrs

Johnny Mack

TITLE
Member of the Corporate Advisory Board
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Apr 19 Sell Rolv Heggenhougen Individual 16. Mar 18 17. Dec 18 -4,880,000 $0.06 $-86,800
01. Apr 19 Sell Rolv Heggenhougen Individual 22. Feb 18 21. Dec 18 -3,266,223 $0.09 $-150,267
01. Apr 19 Sell Marco Alfonsi Individual 11. Jan 18 13. Nov 18 -4,025,000 $0.04 $-106,410
01. Apr 19 Sell Marco Alfonsi Individual 04. Oct 18 08. Nov 18 -875,000 $0.04 $-31,025
X
Management checks
We assess Canbiola's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Canbiola has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Canbiola Inc. develops and sells cannabidiol (CBD) based products for pain, insomnia, epilepsy, anxiety, inflammation, and nausea in the United States. The company provides CBD products derived from hemp, including oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrates, and water through its Website, and doctors and other medical professionals. It also offers WRAPmail, a technology that combines custom marketing content with organization email to provide marketing platform for organizations and personal use; and Bullseye Productivity Suite, a cloud-based system that consolidates office productivity tools into one online experience. The company was formerly known as WRAPmail, Inc. and changed its name to Canbiola, Inc. in May 2017. Canbiola, Inc. was founded in 2005 and is based in Hicksville, New York.

Details
Name: Canbiola, Inc.
CANB
Exchange: OTCPK
Founded: 2005
$22,573,542
578,808,778
Website: http://www.canbiola.com
Address: Canbiola, Inc.
960 South Broadway,
Suite 120,
Hicksville,
New York, 11801,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CANB Common Stock Pink Sheets LLC US USD 11. Mar 2011
Number of employees
Current staff
Staff numbers
4
Canbiola employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 00:25
End of day share price update: 2019/07/17 00:00
Last earnings filing: 2019/05/23
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.